Cell Surface GRP94 as a Novel Emerging Therapeutic Target for Monoclonal Antibody Cancer Therapy

Cells. 2021 Mar 17;10(3):670. doi: 10.3390/cells10030670.

Abstract

Glucose-regulated protein 94 (GRP94) is an endoplasmic reticulum (ER)-resident member of the heat shock protein 90 (HSP90) family. In physiological conditions, it plays a vital role in regulating biological functions, including chaperoning cellular proteins in the ER lumen, maintaining calcium homeostasis, and modulating immune system function. Recently, several reports have shown the functional role and clinical relevance of GRP94 overexpression in the progression and metastasis of several cancers. Therefore, the current review highlights GRP94's physiological and pathophysiological roles in normal and cancer cells. Additionally, the unmet medical needs of small chemical inhibitors and the current development status of monoclonal antibodies specifically targeting GRP94 will be discussed to emphasize the importance of cell surface GRP94 as an emerging therapeutic target in monoclonal antibody therapy for cancer.

Keywords: GRP94; cancer; monoclonal antibody; therapeutic target; therapy.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Antibodies, Monoclonal / therapeutic use*
  • Antineoplastic Agents, Immunological / therapeutic use*
  • Cell Membrane / drug effects
  • Cell Membrane / immunology*
  • Cell Membrane / metabolism
  • Endoplasmic Reticulum / drug effects
  • Endoplasmic Reticulum / metabolism
  • Humans
  • Membrane Glycoproteins / drug effects*
  • Membrane Glycoproteins / immunology
  • Membrane Glycoproteins / metabolism
  • Molecular Chaperones / drug effects
  • Molecular Chaperones / metabolism
  • Neoplasms / drug therapy*
  • Neoplasms / metabolism

Substances

  • Antibodies, Monoclonal
  • Antineoplastic Agents, Immunological
  • Membrane Glycoproteins
  • Molecular Chaperones
  • endoplasmin